On 21st – 22nd June, Oncology Central is hosting a free, CME-accredited, education symposium on the practical clinical aspects of immuno-onoclogy.
Chaired by Professor Angus Dalgleish (St George’s, University of London), our online symposium is aimed at delivering oncology professionals key updates in this field, discussing how practices are changing and what continually emerging data mean for an individual’s own practice.
Over two successive days we aim to review the current status of cancer immunotherapy in the clinic and ask what’s next for this therapeutic modality through the following series of talks delivered by key opinion leaders in the field. You can view the full programme here.
Day 1 – Wednesday 21st June 2017
14:00-14:10 – Welcome
14:15-14:45 – Update on the current status of immunotherapy in clinical practice
Dr. Slovin is Attending Physician and Member in the Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine, Department of Medicine at Joan and Sanford I. Weill Medical College of Cornell University.
14:55-15:25 – PD-1 and PD-L1 inhibitors in melanoma: from first successes to future challenges
15:35-16:05 – Combination vs single agent checkpoint inhibition in solid malignancies
Over the past 35 years, Marc has focused his clinical research in expanding our understanding or the immunobiology of human cancer and the development of new immune therapies for renal cell carcinoma, melanoma and glioblastoma multiforme. He did his cancer immunology and immunotherapy training in the clinical research and laboratory program of John M. Kirkwood while at Yale University and continued his work in translational immunotherapy at Yale (1984-86), the University of Pittsburgh (2986-1991), Geisel School of Medicine (1991-2014), and the Cleveland Clinic (2014-2016). In 2016, Marc became the Chair of the Department of Medicine and Senior Vice President of Clinical Unvestigation at Roswell Park Cancer Institute.
16:15-16:45 – Immunotherapy beyond checkpoint inhibition
Dr. James Gulley, MD, PhD, is Chief, Genitourinary Malignancies Branch; Head of Immunotherapy Section; Director, Medical Oncology Service, National Cancer Institute (NCI). Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer.
For further details, including the programme for the second day of the symposium, click here.